Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Canagliflozin/metformin immediate-release - Johnson & Johnson Innovative Medicine

Next Previous
X
Search
Drug Profile

Canagliflozin/metformin immediate-release - Johnson & Johnson Innovative Medicine

Alternative Names: CANA/MET IR FDC; Invokamet; Metformin immediate-release/canagliflozin - Johnson & Johnson; Metformin immediate-release/canagliflozin - Johnson & Johnson Innovative Medicine; Vokanamet

Latest Information Update: 10 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen Research & Development
  • Developer Janssen Research & Development; Johnson & Johnson Innovative Medicine; Mundipharma Medical Company
  • Class Antihyperglycaemics; Biguanides; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Preregistration Diabetic nephropathies

Most Recent Events

  • 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
  • 15 Nov 2021 Canagliflozin/metformin immediate-release is still in pre-registration phase for diabetic nephropathies in European Union
  • 21 Aug 2019 European Medicines Agency (EMA) accepts the licence extension submission for chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top